Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

[ad_1] HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso’s PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/-…

Arm extends Cortex-M portfolio to bring AI to the smallest endpoint devices – IoT Business News

[ad_1] By Paul Williamson, senior vice president and general manager, IoT Line of Business. News highlights: New Arm Cortex-M52 is the smallest, most area- and cost-efficient processor enabled with Arm…

What Is Small Business Endpoint Security: Meeting your Business Needs

[ad_1] What is Small Business Endpoint Security? What is Small Business Endpoint Security and why do small businesses need it? The crucial role of endpoint security for small businesses is…